Navigation Links
Treatment for extreme nausea, vomiting during pregnancy
Date:5/6/2009

This press release is available in French.

Montreal, May 6, 2009 Nausea and vomiting are telltale indicators of pregnancy, affecting more than 80 percent of future mothers. For a few moms-to-be, symptoms can become so severe that hospitalization is required.

Yet a new medication protocol, introduced by the Sainte-Justine University Hospital Center, appears effective in improving symptoms more quickly and provides a safer option than those previously available. The findings, which are good news for moms and babies, are published in a recent edition of the European Journal of Obstetrics and Gynecology and Reproductive Biology.

"In 2002, we had to quickly change the medication protocol to treat hyperemisis gravidarum (HG), or severe nausea and vomiting of pregnancy, due to a FDA and Health Canada warnings," says senior researcher Anick Brard, a professor at the Universit de Montral's Faculty of Pharmacy and director of the Research Unit on Medications and Pregnancy of the Sainte-Justine University Hospital Center.

"The warning found that a previously used anti-vomiting medication might cause adverse cardiovascular effects in mothers. We had to quickly choose another treatment, which was safer. The current study looks back at the data to evaluate the effectiveness of this treatment."

Metoclopramide versus droperidol

Dr. Brard and her team, which included researchers from the Universit de Bourgogne, evaluated 229 pregnant women who were admitted to hospital and treated for HG. The scientists compared use of the standard drug droperidol versus the administration of a newer medication called metoclopramide.

They found that metoclopramide worked faster to quell symptoms of nausea and vomiting than droperidol. Importantly, they found no evidence that either of these medications increased the birth defect rate compared to women who received no medication. As expected, metoclopramide was not associated with other serious side effects.

"This study validates our protocol," says Dr. Brard. "Clinical trials are not conducted on pregnant women, so we had to rely on data from prospective and retrospective studies in this case. We anticipate that other institutions will now be comfortable adopting this new treatment regime.

About hyperemis gravidarum

Hyperemis gravidarum, or severe nausea and vomiting of pregnancy, affects about one percent of pregnant women. If left untreated, it can result in severe weight loss, dehydration, or death. Symptoms to look out for include severe vomiting and nausea; incapacity to keep food down for two to three days; lack of energy.

According to Dr. Brard, women should not wait too long before seeking medical help. "The longer the symptoms continue, the longer the hospital stay," she says, adding most women with HG leave the hospital within three days and many are required to take medication throughout their pregnancy.

About the study:

"Metoclopramide and diphenhydramine in the treatment of hyperemisis gravidarum: Effectiveness and predictors of rehospitalization," published in European Journal of Obstetrics and Gynecology and Reproductive Biology, was authored by Anais Lacasse, Ema Ferreira and Anick Brard of the Universit de Montral and the Sainte-Justine University Hospital Centre and Amandine Lagoutte of the Universit de Bourgogne.


'/>"/>

Contact: Sylvain-Jacques Desjardins
sylvain-jacques.desjardins@umontreal.ca
514-343-7593
University of Montreal
Source:Eurekalert

Related biology news :

1. Nicotinic receptors may be important targets for treatment of multiple addictions
2. A new radiation therapy treatment developed for head and neck cancer patients
3. Restoring sight, advances in fertility treatments and better visibility for pilots at FIO
4. Presence of gene mutation helps guide thyroid cancer treatment
5. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
6. New genetic research into nicotine addiction shows promise for personalized treatment
7. Interleukin-8, key marker for colorectal cancer treatment
8. New class of drug offers hope to treatment-resistant AIDS patients
9. Paradigm shift in Alzheimerss research: new treatments
10. New research on structure of bones raises questions for treatment of osteoporosis
11. Major genetic breakthrough for ankylosing spondylitis brings treatment hope
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)...  Regular discussions on a range of subjects including policies, ... entities said Poloz. Speaking at a lecture to ... he pointed to the country,s inflation target, which is set ... "In certain areas there needs ... economic goals, why not sit down and address strategy together?" ...
Breaking Biology Technology: